Lymphoma Clinical Trials in Dallas

Showing 181-200 of 245 trials

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

NCT02214147

The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.

Advanced Solid TumorsRelapsed/Refractory Lymphoma

Millennium Pharmaceuticals, Inc.36 participantsStarted Aug 2014

Miami, Florida, United States • Chicago, Illinois, United States • Ann Arbor, Michigan, United States +4 more locations

COMPLETED< 1 mile

Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma

NCT00091091

RATIONALE: Assessing the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care. PURPOSE: This clinical trial is studying the long-term effects of treatment in patients who were previously treated for childhood Hodgkin's lymphoma.

Long-term Effects Secondary to Cancer Therapy in ChildrenLymphoma

Children's Oncology Group530 participantsStarted Dec 2004

Palo Alto, California, United States • New Haven, Connecticut, United States • Chicago, Illinois, United States +12 more locations

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Other Conditions in Dallas